Market Overview

UPDATE: Piper Jaffray Initiates Idera Pharmaceuticals at Overweight on Encouraging Data

Share:
Related IDRA
Benzinga's Top Upgrades, Downgrades For November 9, 2017
40 Biggest Movers From Yesterday

Piper Jaffray initiated overage on Idera Pharmaceuticals (NASDAQ: IDRA) with an Overweight rating and a $2 price target.

Piper Jaffray commented, "Idera is developing IMO-3100, a TLR 7 and 9 antagonist, for the treatment of lupus. The company recently reported top-line data from a 4-week Phase IIa study of IMO-3100 in moderate-to-severe psoriasis showing a statistically significant improvement in the Psoriasis Area Severity Index (PASI) score over placebo. Not only do these results demonstrate proof-ofconcept for IMO-3100 in psoriasis, but more broadly Idera's approach of modulating TLRs to treat autoimmune disorders. The company next intends to conduct a larger, 12-week Phase IIb trial in early 2013. IMO-3100 offers a unique mechanism of action in a disease that needs novel therapies and could represent a blockbuster opportunity."

Idera Pharmaceuticals closed at $0.80 on Wednesday.

Latest Ratings for IDRA

DateFirmActionFromTo
Nov 2017H.C. WainwrightInitiates Coverage OnBuy
Apr 2017BairdInitiates Coverage OnOutperform
Mar 2017JMP SecuritiesInitiates Coverage OnMarket Outperform

View More Analyst Ratings for IDRA
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (IDRA)

View Comments and Join the Discussion!

Partner Center